STXBP6

Across TCGA pan-cancer cohorts, STXBP6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated STXBP6 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher STXBP6 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated STXBP6 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, LUAD, and COAD are the cancer types where STXBP6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.994	0.676	.004	12	view →
LUAD	DFS	Median	All	0.850	0.945	.001	8	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
LSCC	OS	Median	II,III,IV	0.944	0.778	.028	4	view →
UCEC	DFS	Quartile	All	0.965	0.743	.020	4	view →
HNSC	OS	Median	II,III,IV	0.816	0.623	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

STXBP6–PDAC (OS)

Open the PDAC breakdown →